AI is spitting out more potential drugs than ever. This startup wants to figure out which ones matter.
10x Science, a startup founded in December 2025, has raised $4.8 million to help pharmaceutical researchers characterize potential drug candidates generated by AI, addressing a bottleneck in drug development. The platform combines chemistry, biology, and AI to interpret complex data from mass spectrometry, aiming to streamline the drug discovery process and enhance regulatory compliance.
10x Science's platform, which combines deterministic algorithms with AI to interpret mass spectrometry data, offers a scalable solution for drug discovery by streamlining the characterization of complex molecules. This approach could significantly reduce time and resource expenditure in biotech startups, making it a potentially valuable investment opportunity in the healthtech space.